Michael L. Jackson, PhD, MPH, focuses on understanding how infectious diseases spread, and on designing and evaluating interventions such as vaccination programs. Dr. Jackson is the Kaiser Permanente Washington Health Research Institute (KPWHRI) principal investigator for the United States Influenza Vaccine Effectiveness (US Flu VE) Network. Using information from five sites across the country, including Kaiser Permanente Washington, this network aims to provide ongoing evaluations of the U.S. influenza vaccination program. Dr. Jackson uses data from this network to study influenza vaccine effectiveness, to estimate the burden of disease caused by influenza, and to advance the methodology of vaccine effectiveness studies.
In addition, Dr. Jackson is using data collected by the US Flu VE Network to build a simulation model for the spread of influenza, with a specific focus on understanding when new strains of the influenza virus can out-compete existing strains. This work, funded by the National Institutes of Health, aims to improve our ability to correctly choose which strains of the influenza virus to include in seasonal influenza vaccines. He also uses simulation models to predict the impact of vaccination programs on the spread of infectious diseases such as Haemophilus influenzae type b (Hib) and Neisseria meningitidis.
Dr. Jackson is a co-investigator on the Vaccine Safety Datalink (VSD) Project. The VSD, a collaboration among nine U.S. managed care organizations and the Centers for Disease Control and Prevention (CDC), is the world’s premier system for post-licensure studies of vaccine safety. As a VSD co-investigator, Dr. Jackson leads studies of the safety of childhood immunizations and develops methods for using managed care data for vaccine safety studies.
While studying for his PhD at the University of Washington, Dr. Jackson was a graduate research associate with KPWHRI from 2002 to 2007, and then a postdoctoral fellow at KPWHRI from 2007 to 2008. He then spent two years as an Epidemic Intelligence Service (EIS) officer with the CDC in Atlanta. As an EIS officer, Dr. Jackson helped lead investigations of whooping cough outbreaks and of the 2009 influenza pandemic. He also designed and oversaw an enhanced surveillance system for invasive Hib disease in the U.S. during the 2008–2009 shortage of Hib vaccines. He returned to KPWHRI as an assistant investigator in 2010. He is an affiliate associate professor at the University of Washington School of Public Health.
Zhou H, Thompson WW, Belongia EA, Fowlkes A, Baxter R, Jacobsen SJ, Jackson ML, Glanz JM, Naleway AL, Ford DC, Weintraub E, Shay DK. Estimated rates of influenza-associated outpatient visits during 2001-2010 in six US integrated health care delivery organizations. Influenza Other Respir Viruses. 2018 Jan;12(1):122-131. doi: 10.1111/irv.12495. Epub 2018 Feb 15. PubMed
Chang AY, Riumallo-Herl C, Perales NA, Clark S, Clark A, Constenla D, Garske T, Jackson ML, Jean K, Jit M, Jones EO, Li X, Suraratdecha C, Bullock O, Johnson H, Brenzel L, Verguet S. The equity impact vaccines may have on averting deaths and medical impoverishment in developing countries. Health Aff (Millwood). 2018 Feb;37(2):316-324. doi: 10.1377/hlthaff.2017.0861. PubMed
Flannery B, Smith C, Garten RJ, Levine MZ, Chung JR, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman R, Nowalk MP, Griffin MR, Keipp Talbot H, Treanor JJ, Wentworth DE, Fry AM. Influence of birth cohort on effectiveness of 2015-2016 influenza vaccine against medically attended illness due to 2009 pandemic influenza A(H1N1) virus in the United States. J Infect Dis. 2018 Jun 20;218(2):189-196. doi: 10.1093/infdis/jix634. PubMed
Jackson ML, Diallo AO, Medah I, Bicaba BW, Yameogo I, Koussoube D, Ouedraogo R, Sangare L, Mbaeyi SA. Initial validation of a simulation model for estimating the impact of serogroup A Neisseria meningitidis vaccination in the African meningitis belt. PLoS One. 2018 Oct 25;13(10):e0206117. doi: 10.1371/journal.pone.0206117. eCollection 2018. PubMed
Jackson ML, Phillips CH, Benoit J, Kiniry E, Madziwa L, Nelson JC, Jackson LA. The impact of selection bias on vaccine effectiveness estimates from test-negative studies. Vaccine. 2018 Jan 29;36(5):751-757. doi: 10.1016/j.vaccine.2017.12.022. Epub 2017 Dec 15. PubMed
Jackson ML, Phillips CH, Benoit J, Jackson LA, Gaglani M, Murthy K, McLean HQ, Belongia EA, Malosh R, Zimmerman R, Flannery B. Burden of medically attended influenza infection and cases averted by vaccination - United States, 2013/14 through 2015/16 influenza seasons. Vaccine. 2018 Jan 25;36(4):467-472. doi: 10.1016/j.vaccine.2017.12.014. Epub 2017 Dec 14. PubMed
Daley MF, Clarke CL, Glanz JM, Xu S, Hambidge SJ, Donahue JG, Nordin JD, Klein NP, Jacobsen SJ, Naleway AL, Jackson ML, Lee G, Duffy J, Weintraub E. The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: a Vaccine Safety Datalink study. Pharmacoepidemiol Drug Saf. 2018 Jan;27(1):59-68. doi: 10.1002/pds.4349. Epub 2017 Nov 17. PubMed
McCarthy NL, Sukumaran L, Newcomer S, Glanz J, Daley MF, McClure D, Klein NP, Irving S, Jackson ML, Lewin B, Weintraub E. Patterns of childhood immunization and all-cause mortality. Vaccine. 2017 Oct 20. pii: S0264-410X(17)31442-1. doi: 10.1016/j.vaccine.2017.10.034. [Epub ahead of print]. PubMed
Lipkind HS, Vazquez-Benitez G, Nordin JD, Romitti PA, Naleway AL, Klein NP, Hechter RC, Jackson ML, Hambidge SJ, Lee GM, Sukumaran L, Kharbanda EO. Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy. Obstet Gynecol. 2017;130(3):599-608. doi: 10.1097/AOG.0000000000002191. PubMed
Texier G, Jackson ML, Siwe L, Meynard JB, Deparis X, Chaudet H. Building test data from real outbreaks for evaluating detection algorithms. PLoS One. 2017 Sep 1;12(9):e0183992. doi: 10.1371/journal.pone.0183992. eCollection 2017. PubMed
Dr. Paula Lozano explains how a Learning Health System project finds Kaiser Permanente Washington members who could benefit most from preventive services.
New KPWHRI study helps confirm national guidelines that encourage people with high-risk conditions to get the shot.
Read more in Healthy Findings.
While flu vaccine effectiveness varies year to year, it still makes sense to get immunized annually.
Read about it in Live Healthy.
K5 News, Dec 2, 2019